Neuroscience
| 5 min read
Montara Therapeutics is taking a different approach to CNS drug development by using the blood-brain barrier to restrict drug activity outside the brain and reduce dose-limiting toxicities.
| 4 min read
By tracking how cells respond to hundreds of thousands of compounds, Soley Therapeutics aims to discover medicines for complex diseases where traditional target-based approaches often fall short.
| 3 min read
Voyager Therapeutics’ promising toxicology data in non-human primates suggests their proprietary capsid technology could deliver long-lasting results in Alzheimer’s disease.
| 4 min read
Psychedelic acquisitions, clinical trial updates, and more led the news this week.
| 3 min read
A new platform combines engineered viral vectors with the brain's glymphatic system to improve gene delivery to glial cells implicated in multiple neurological disorders.
| 3 min read
KCL-286 repaired neuronal DNA damage and reduced neuroinflammation in mice, with prior Phase 1 safety data potentially accelerating its path to Alzheimer's trials.
| 4 min read
Phase 3 trial results for neurological drugs, an AI platform for central nervous system drug discovery, a novel long-acting flu antiviral, and more led the news this week.
| 3 min read
Some people with amyloid plaques and tau tangles in their brain never develop Alzheimer’s disease. New research suggests it comes down to microglial activity.
Advanced microelectrode array and liquid handling technologies make neuronal culture screening more consistent and easier to scale.
| 5 min read
A first-in-class synaptic regenerative approach shows promise across multiple neurodegenerative and neuropsychiatric diseases.
| 3 min read
Using an unbiased molecular screen, researchers found a new gene that could be targeted to treat fragile X syndrome.
| 3 min read
It’s long been recognized that obesity in midlife significantly raises the risk of Alzheimer’s disease. A new study shows the biological mechanisms that contribute to pathogenesis.
